FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.
You may also be interested in...
Remote Monitoring A Potential Strategy To Recruit Older Adults Into Oncology Trials
Final FDA guidance also suggests sponsors recruit representative populations and limit exclusions.
New Acting US FDA Commissioner Shares Agency's Clinical Trial Reform Message
Norman Sharpless, director of the National Cancer Institute, will become acting FDA commissioner when Scott Gottlieb departs.
Large Simple Trials Need FDA Boost, IoM Report Says
“Clear specific guidance” from the agency would help close the perception gap between what types of data industry thinks FDA wants and what the agency actually expects, according to a summary of a 2012 Institute of Medicine workshop.